|
1
|
Matteson NL, Hassler GW, Kurzban E, Schwab MA, Perkins SA, Gangavarapu K, Levy JI, Parker E, Pride D, Hakim A, De Hoff P, Cheung W, Castro-Martinez A, Rivera A, Veder A, Rivera A, Wauer C, Holmes J, Wilson J, Ngo SN, Plascencia A, Lawrence ES, Smoot EW, Eisner ER, Tsai R, Chacón M, Baer NA, Seaver P, Salido RA, Aigner S, Ngo TT, Barber T, Ostrander T, Fielding-Miller R, Simmons EH, Zazueta OE, Serafin-Higuera I, Sanchez-Alavez M, Moreno-Camacho JL, García-Gil A, Murphy Schafer AR, McDonald E, Corrigan J, Malone JD, Stous S, Shah S, Moshiri N, Weiss A, Anderson C, Aceves CM, Spencer EG, Hufbauer EC, Lee JJ, King AJ, Ramesh KS, Nguyen KN, Saucedo K, Robles-Sikisaka R, Fisch KM, Gonias SL, Birmingham A, McDonald D, Karthikeyan S, Martin NK, Schooley RT, Negrete AJ, Reyna HJ, Chavez JR, Garcia ML, Cornejo-Bravo JM, Becker D, Isaksson M, Washington NL, Lee W, Garfein RS, Luna-Ruiz Esparza MA, Alcántar-Fernández J, Henson B, Jepsen K, Olivares-Flores B, Barrera-Badillo G, Lopez-Martínez I, Ramírez-González JE, Flores-León R, Kingsmore SF, Sanders A, Pradenas A, White B, Matthews G, Hale M, McLawhon RW, Reed SL, Winbush T, McHardy IH, Fielding RA, Nicholson L, Quigley MM, Harding A, Mendoza A, Bakhtar O, Browne SH, Olivas Flores J, Rincon Rodríguez DG, Gonzalez Ibarra M, Robles Ibarra LC, Arellano Vera BJ, Gonzalez Garcia J, Harvey-Vera A, Knight R, Laurent LC, Yeo GW, Wertheim JO, Ji X, Worobey M, Suchard MA, Andersen KG, Campos-Romero A, Wohl S, Zeller M. Genomic surveillance reveals dynamic shifts in the connectivity of COVID-19 epidemics. Cell 2023; 186:5690-5704.e20. [PMID: 38101407 PMCID: PMC10795731 DOI: 10.1016/j.cell.2023.11.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 08/21/2023] [Accepted: 11/21/2023] [Indexed: 12/17/2023]
Abstract
The maturation of genomic surveillance in the past decade has enabled tracking of the emergence and spread of epidemics at an unprecedented level. During the COVID-19 pandemic, for example, genomic data revealed that local epidemics varied considerably in the frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage importation and persistence, likely due to a combination of COVID-19 restrictions and changing connectivity. Here, we show that local COVID-19 epidemics are driven by regional transmission, including across international boundaries, but can become increasingly connected to distant locations following the relaxation of public health interventions. By integrating genomic, mobility, and epidemiological data, we find abundant transmission occurring between both adjacent and distant locations, supported by dynamic mobility patterns. We find that changing connectivity significantly influences local COVID-19 incidence. Our findings demonstrate a complex meaning of "local" when investigating connected epidemics and emphasize the importance of collaborative interventions for pandemic prevention and mitigation.
Collapse
Affiliation(s)
| | - Gabriel W Hassler
- Department of Computational Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - Ezra Kurzban
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Madison A Schwab
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Sarah A Perkins
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Karthik Gangavarapu
- Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Joshua I Levy
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Edyth Parker
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - David Pride
- Department of Pathology, University of California, San Diego, La Jolla, CA, USA; Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Abbas Hakim
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; COVID-19 Detection, Investigation, Surveillance, Clinical, and Outbreak Response, California Department of Public Health, Richmond, CA, USA
| | - Peter De Hoff
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; COVID-19 Detection, Investigation, Surveillance, Clinical, and Outbreak Response, California Department of Public Health, Richmond, CA, USA
| | - Willi Cheung
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; COVID-19 Detection, Investigation, Surveillance, Clinical, and Outbreak Response, California Department of Public Health, Richmond, CA, USA
| | - Anelizze Castro-Martinez
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium of Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Andrea Rivera
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Anthony Veder
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Ariana Rivera
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Cassandra Wauer
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Jacqueline Holmes
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Jedediah Wilson
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Shayla N Ngo
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Ashley Plascencia
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Elijah S Lawrence
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Elizabeth W Smoot
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Emily R Eisner
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Rebecca Tsai
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Marisol Chacón
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Nathan A Baer
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Phoebe Seaver
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Rodolfo A Salido
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Stefan Aigner
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Toan T Ngo
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Tom Barber
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Tyler Ostrander
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Rebecca Fielding-Miller
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA; Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA, USA
| | | | - Oscar E Zazueta
- Department of Epidemiology, Secretaria de Salud de Baja California, Tijuana, Baja California, Mexico
| | | | - Manuel Sanchez-Alavez
- Centro de Diagnostico COVID-19 UABC, Tijuana, Baja California, Mexico; Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA
| | | | - Abraham García-Gil
- Clinical Laboratory Department, Salud Digna, A.C, Tijuana, Baja California, Mexico
| | | | - Eric McDonald
- County of San Diego Health and Human Services Agency, San Diego, CA, USA
| | - Jeremy Corrigan
- County of San Diego Health and Human Services Agency, San Diego, CA, USA
| | - John D Malone
- County of San Diego Health and Human Services Agency, San Diego, CA, USA
| | - Sarah Stous
- County of San Diego Health and Human Services Agency, San Diego, CA, USA
| | - Seema Shah
- County of San Diego Health and Human Services Agency, San Diego, CA, USA
| | - Niema Moshiri
- Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA, USA
| | - Alana Weiss
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Catelyn Anderson
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Christine M Aceves
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Emily G Spencer
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Emory C Hufbauer
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Justin J Lee
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Alison J King
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Karthik S Ramesh
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Kelly N Nguyen
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Kieran Saucedo
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | | | - Kathleen M Fisch
- Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; Center for Computational Biology and Bioinformatics, University of California San Diego, La Jolla, CA, USA
| | - Steven L Gonias
- Department of Pathology, University of California, San Diego, La Jolla, CA, USA
| | - Amanda Birmingham
- Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Daniel McDonald
- Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Smruthi Karthikeyan
- Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
| | - Natasha K Martin
- Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA, USA
| | - Robert T Schooley
- Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA, USA
| | - Agustin J Negrete
- Facultad de Ciencias de la Salud Universidad Autonoma de Baja California Valle de Las Palmas, Tijuana, Baja California, Mexico
| | - Horacio J Reyna
- Facultad de Ciencias de la Salud Universidad Autonoma de Baja California Valle de Las Palmas, Tijuana, Baja California, Mexico
| | - Jose R Chavez
- Facultad de Ciencias de la Salud Universidad Autonoma de Baja California Valle de Las Palmas, Tijuana, Baja California, Mexico
| | - Maria L Garcia
- Facultad de Ciencias de la Salud Universidad Autonoma de Baja California Valle de Las Palmas, Tijuana, Baja California, Mexico
| | - Jose M Cornejo-Bravo
- Facultad de Ciencias Quimicas e Ingenieria, Universidad Autonoma de Baja California, Tijuana, Baja California, Mexico
| | | | | | | | | | - Richard S Garfein
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA
| | | | | | - Benjamin Henson
- Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Kristen Jepsen
- Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Beatriz Olivares-Flores
- Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, CDMX, Mexico
| | - Gisela Barrera-Badillo
- Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, CDMX, Mexico
| | - Irma Lopez-Martínez
- Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, CDMX, Mexico
| | - José E Ramírez-González
- Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, CDMX, Mexico
| | - Rita Flores-León
- Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, CDMX, Mexico
| | | | - Alison Sanders
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Allorah Pradenas
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Benjamin White
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Gary Matthews
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Matt Hale
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Ronald W McLawhon
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Sharon L Reed
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | - Terri Winbush
- Return to Learn, University of California, San Diego, La Jolla, CA, USA
| | | | | | | | | | | | | | | | - Sara H Browne
- Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA, USA; Specialist in Global Health, Encinitas, CA, USA
| | - Jocelyn Olivas Flores
- Facultad de Ciencias Quimicas e Ingenieria, Universidad Autonoma de Baja California, Tijuana, Baja California, Mexico; University of HealthMx, Tijuana, Baja California, Mexico
| | - Diana G Rincon Rodríguez
- University of HealthMx, Tijuana, Baja California, Mexico; Facultad de Medicina, Universidad Xochicalco, Tijuana, Baja California, Mexico
| | - Martin Gonzalez Ibarra
- University of HealthMx, Tijuana, Baja California, Mexico; Facultad de Medicina, Universidad Xochicalco, Tijuana, Baja California, Mexico
| | - Luis C Robles Ibarra
- University of HealthMx, Tijuana, Baja California, Mexico; Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Tijuana, Baja California, Mexico
| | - Betsy J Arellano Vera
- University of HealthMx, Tijuana, Baja California, Mexico; Instituto Mexicano del Seguro Social, Tijuana, Baja California, Mexico
| | - Jonathan Gonzalez Garcia
- University of HealthMx, Tijuana, Baja California, Mexico; SIMNSA, Tijuana, Baja California, Mexico
| | | | - Rob Knight
- Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA, USA; Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA
| | - Louise C Laurent
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium of Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Gene W Yeo
- Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium of Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Joel O Wertheim
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Xiang Ji
- Department of Mathematics, School of Science and Engineering, Tulane University, New Orleans, LA, USA
| | - Michael Worobey
- Department of Ecology and Evolutionary Biology, University of Arizona, Tucson, AZ, USA
| | - Marc A Suchard
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Kristian G Andersen
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
| | - Abraham Campos-Romero
- Innovation and Research Department, Salud Digna, A.C, Tijuana, Baja California, Mexico
| | - Shirlee Wohl
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA
| | - Mark Zeller
- Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
| |
Collapse
|
|
2
|
Ana RD, Gliszczyńska A, Sanchez-Lopez E, Garcia ML, Krambeck K, Kovacevic A, Souto EB. Precision Medicines for Retinal Lipid Metabolism-Related Pathologies. J Pers Med 2023; 13:jpm13040635. [PMID: 37109021 PMCID: PMC10145959 DOI: 10.3390/jpm13040635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/01/2023] [Accepted: 04/04/2023] [Indexed: 04/29/2023] Open
Abstract
Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch's membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.
Collapse
Affiliation(s)
- Raquel da Ana
- UCIBIO-Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Anna Gliszczyńska
- Department of Food Chemistry and Biocatalysis, Faculty of Biotechnology and Food Science, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland
| | - Elena Sanchez-Lopez
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08007 Barcelona, Spain
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08007 Barcelona, Spain
- Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034 Barcelona, Spain
| | - Maria L Garcia
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08007 Barcelona, Spain
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08007 Barcelona, Spain
| | - Karolline Krambeck
- UCIBIO-Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Health Sciences School, Guarda Polytechnic Institute, 6300-035 Guarda, Portugal
| | - Andjelka Kovacevic
- Department of Pharmaceutical Technology, Institute of Pharmacy, Friedrich Schiller University Jena, 07743 Jena, Germany
| | - Eliana B Souto
- UCIBIO-Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| |
Collapse
|
|
3
|
Fernandes AR, Vidal LB, Sánchez-López E, Dos Santos T, Granja PL, Silva AM, Garcia ML, Souto EB. Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes. Int J Pharm 2022; 623:121938. [PMID: 35728716 DOI: 10.1016/j.ijpharm.2022.121938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 06/11/2022] [Accepted: 06/14/2022] [Indexed: 11/17/2022]
Abstract
Customized cationic oil-in-water nanoemulsions (NEs) have been produced to improve the bioavailability of poorly water-soluble drugs, such as triamcinolone acetonide (TA). TA is a synthetic glucocorticoid with anti-inflammatory and antiangiogenic therapeutic properties and it is widely used as an effective treatment in ocular disorders. In this work, TA-NEs were characterized using two different custom-made cationic surfactants, showing a high positive surface charge favouring corneal penetration and a particle size below 300 nm. Both TA-NE formulations demonstrated to be stable at 4 °C during the first months of storage. Furthermore, TA-NEs were able to produce antiangiogenic effects in chicken membranes. The TA-NEs safety profile was evaluated using in vitro and in vivo ocular tolerance tests. Out of the two formulations, the one showing no irritant effects was screened in vivo demonstrating capacity to ameliorate ocular inflammation in New Zealand rabbits significantly, specially to reduce the risk of ocular inflammation processes, with antiangiogenic activity, and can therefore be exploited as a suitable formulation to avoid inflammatory reactions upon ocular surgical procedures, such as cataracts.
Collapse
Affiliation(s)
- Ana R Fernandes
- i3s - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal; Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - Lorena B Vidal
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain
| | - Elena Sánchez-López
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain; Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034 Barcelona, Spain; Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain
| | - Tiago Dos Santos
- i3s - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Pedro L Granja
- i3s - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Amelia M Silva
- Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal.
| | - Maria L Garcia
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain
| | - Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy of University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal; REQUIMTE/UCIBIO, Faculty of Pharmacy of University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
| |
Collapse
|
|
4
|
Fernandes AR, Dos Santos T, Granja PL, Sanchez-Lopez E, Garcia ML, Silva AM, Souto EB. Permeability, anti-inflammatory and anti-VEGF profiles of steroidal-loaded cationic nanoemulsions in retinal pigment epithelial cells under oxidative stress. Int J Pharm 2022; 617:121615. [PMID: 35217072 DOI: 10.1016/j.ijpharm.2022.121615] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 02/08/2022] [Accepted: 02/20/2022] [Indexed: 12/19/2022]
Abstract
Age-related macular degeneration (AMD) is defined as a degenerative, progressive and multifactorial disorder that affects the macula with a complex etiology. The retinal pigment epithelium is a monolayer of cells that has the function to separate the surface of the choroid from the neural retina that is involved in the signal transduction leading to vision. The blood-aqueous barrier and the blood retinal barrier limit the permeation of drugs into the retina and thereby reducing their efficacy. Triamcinolone acetonide (TA) is widely used as anti-inflammatory and immunomodulatory drug that promotes the inhibition of the inflammatory processes. The factors that stimulate or inhibit angiogenesis in AMD create a local balance that is responsible for the growth of sub-retinal neovascularization. In AMD, the main angiogenic stimulus is the vascular endothelial growth factor (VEGF). In this work, nanoemulsions with cationic surfactants (mono- and dicationic DABCO and quinuclidine) were produced to deliver TA, and were found to reduce the production of tumor necrosis factor alpha (TNF-α), which stimulates the choroidal neovascularization development by upregulating the VEGF production, and consequently decreased the VEGF levels. Our results support the potential use of mono- and dicationic DABCO and quinuclidine-based cationic nanoemulsions for the delivery of TA in the treatment of AMD.
Collapse
Affiliation(s)
- Ana R Fernandes
- i3S - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering National Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal; Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - Tiago Dos Santos
- i3S - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering National Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Pedro L Granja
- i3S - Institute for Research & Innovation in Health, University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Biomedical Engineering National Institute, University of Porto, Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Elena Sanchez-Lopez
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain
| | - Maria L Garcia
- Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - Amelia M Silva
- Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal.
| | - Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; LABBELS - Associate Laboratory, Braga, Guimarães, Portugal.
| |
Collapse
|
|
5
|
Garcia ML, Starr MR, Smith WM. Middle-aged Woman With Optic Neuritis and a Rapidly Progressing Retinal Vaso-occlusive Disease. JAMA Ophthalmol 2021; 138:797-798. [PMID: 32463455 DOI: 10.1001/jamaophthalmol.2020.0605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Maria L Garcia
- Mayo Clinic Department of Ophthalmology, Rochester, Minnesota
| | - Matthew R Starr
- The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania
| | - Wendy M Smith
- Mayo Clinic Department of Ophthalmology, Rochester, Minnesota
| |
Collapse
|
|
6
|
Sánchez-López E, Gomes D, Esteruelas G, Bonilla L, Lopez-Machado AL, Galindo R, Cano A, Espina M, Ettcheto M, Camins A, Silva AM, Durazzo A, Santini A, Garcia ML, Souto EB. Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. Nanomaterials (Basel) 2020; 10:E292. [PMID: 32050443 PMCID: PMC7075170 DOI: 10.3390/nano10020292] [Citation(s) in RCA: 453] [Impact Index Per Article: 113.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Revised: 01/27/2020] [Accepted: 01/29/2020] [Indexed: 02/07/2023]
Abstract
Metal-based nanoparticles have been extensively investigated for a set of biomedical applications. According to the World Health Organization, in addition to their reduced size and selectivity for bacteria, metal-based nanoparticles have also proved to be effective against pathogens listed as a priority. Metal-based nanoparticles are known to have non-specific bacterial toxicity mechanisms (they do not bind to a specific receptor in the bacterial cell) which not only makes the development of resistance by bacteria difficult, but also broadens the spectrum of antibacterial activity. As a result, a large majority of metal-based nanoparticles efficacy studies performed so far have shown promising results in both Gram-positive and Gram-negative bacteria. The aim of this review has been a comprehensive discussion of the state of the art on the use of the most relevant types of metal nanoparticles employed as antimicrobial agents. A special emphasis to silver nanoparticles is given, while others (e.g., gold, zinc oxide, copper, and copper oxide nanoparticles) commonly used in antibiotherapy are also reviewed. The novelty of this review relies on the comparative discussion of the different types of metal nanoparticles, their production methods, physicochemical characterization, and pharmacokinetics together with the toxicological risk encountered with the use of different types of nanoparticles as antimicrobial agents. Their added-value in the development of alternative, more effective antibiotics against multi-resistant Gram-negative bacteria has been highlighted.
Collapse
Affiliation(s)
- Elena Sánchez-López
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
| | - Daniela Gomes
- Faculty of Pharmacy (FFUC), Department of Pharmaceutical Technology, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal;
| | - Gerard Esteruelas
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
| | - Lorena Bonilla
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
| | - Ana Laura Lopez-Machado
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
| | - Ruth Galindo
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
| | - Amanda Cano
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
| | - Marta Espina
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
| | - Miren Ettcheto
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
- Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
| | - Antoni Camins
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
- Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
| | - Amélia M. Silva
- Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal;
- Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal
| | - Alessandra Durazzo
- CREA—Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy;
| | - Antonello Santini
- Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy;
| | - Maria L. Garcia
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain; (G.E.); (L.B.); (A.L.L.-M.); (R.G.); (A.C.); (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain; (M.E.); (A.C.)
| | - Eliana B. Souto
- Faculty of Pharmacy (FFUC), Department of Pharmaceutical Technology, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal;
- CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
| |
Collapse
|
|
7
|
Souto EB, Dias-Ferreira J, Oliveira J, Sanchez-Lopez E, Lopez-Machado A, Espina M, Garcia ML, Souto SB, Martins-Gomes C, Silva AM. Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems. Int J Mol Sci 2019; 20:ijms20225659. [PMID: 31726723 PMCID: PMC6888057 DOI: 10.3390/ijms20225659] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 11/06/2019] [Accepted: 11/11/2019] [Indexed: 02/06/2023] Open
Abstract
Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.
Collapse
Affiliation(s)
- Eliana B. Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal; (J.D.-F.); (J.O.); (E.S.-L.); (A.L.-M.)
- CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal
- Correspondence: ; Tel.: +351-239-488-400
| | - João Dias-Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal; (J.D.-F.); (J.O.); (E.S.-L.); (A.L.-M.)
| | - Jéssica Oliveira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal; (J.D.-F.); (J.O.); (E.S.-L.); (A.L.-M.)
| | - Elena Sanchez-Lopez
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal; (J.D.-F.); (J.O.); (E.S.-L.); (A.L.-M.)
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Ave. Joan XXIII, 08028 Barcelona, Spain; (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona 08028, Spain
| | - Ana Lopez-Machado
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal; (J.D.-F.); (J.O.); (E.S.-L.); (A.L.-M.)
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Ave. Joan XXIII, 08028 Barcelona, Spain; (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona 08028, Spain
| | - Marta Espina
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Ave. Joan XXIII, 08028 Barcelona, Spain; (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona 08028, Spain
| | - Maria L. Garcia
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Ave. Joan XXIII, 08028 Barcelona, Spain; (M.E.); (M.L.G.)
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona 08028, Spain
| | - Selma B. Souto
- Department of Endocrinology, Hospital de São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal;
| | - Carlos Martins-Gomes
- Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal; (C.M.-G.); (A.M.S.)
- Department of Biology and Environment, University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal
| | - Amélia M. Silva
- Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal; (C.M.-G.); (A.M.S.)
- Department of Biology and Environment, University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal
| |
Collapse
|
|
8
|
Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol 2019; 29:1211-1219. [PMID: 29438522 DOI: 10.1093/annonc/mdy061] [Citation(s) in RCA: 108] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Background RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status before anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer. Here we compared plasma with tissue RAS analysis in a large prospective multicenter cohort. Patients and methods Plasma samples were collected prospectively from chemotherapy-naive patients and analyzed centrally by next-generation sequencing (NGS) with the colon lung cancer V2 Ampliseq panel and by methylation digital PCR (WIF1 and NPY genes). Tumoral RAS status was determined locally, in parallel, according to routine practice. For a minimal κ coefficient of 0.7, reflecting acceptable concordance (precision ± 0.07), with an estimated 5% of non-exploitable data, 425 subjects were necessary. Results From July 2015 to December 2016, 425 patients were enrolled. For the 412 patients with available paired plasma and tumor samples, the κ coefficient was 0.71 [95% confidence interval (CI), 0.64-0.77] and accuracy was 85.2% (95% CI, 81.4% to 88.5%). In the 329 patients with detectable ctDNA (at least one mutation or one methylated biomarker), the κ coefficient was 0.89 (95% CI, 0.84-0.94) and accuracy was 94.8% (95% CI, 91.9% to 97.0%). The absence of liver metastases was the main clinical factor associated with inconclusive circulating tumor DNA results [odds ratio = 0.11 (95% CI, 0.06-0.21)]. In patients with liver metastases, accuracy was 93.5% with NGS alone and 97% with NGS plus the methylated biomarkers. Conclusion This prospective trial demonstrates excellent concordance between RAS status in plasma and tumor tissue from patients with colorectal cancer and liver metastases, thus validating plasma testing for routine RAS mutation analysis in these patients. Clinical Trial registration Clinicaltrials.gov, NCT02502656.
Collapse
Affiliation(s)
- J B Bachet
- Sorbonne Universités, UPMC Université, Paris; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris; Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris; AGEO (Association des Gastroentérologues Oncologues), Paris
| | - O Bouché
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Hepato-Gastroenterology, Hôpital Robert Debré, Reims
| | - J Taieb
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Digestive Oncology, Hôpital Européen Georges Pompidou, Paris
| | - O Dubreuil
- Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris; AGEO (Association des Gastroentérologues Oncologues), Paris
| | - M L Garcia
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Oncology, Hôpital Saint-Antoine, Paris
| | - A Meurisse
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - C Normand
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris
| | - J M Gornet
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Saint-Louis, Paris
| | - P Artru
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Privé Jean Mermoz, Lyon
| | - S Louafi
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes; Department of Gastroenterology, Groupe Hospitalier Nord Essonne, Longjumeau
| | - F Bonnetain
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - A Thirot-Bidault
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Kremlin Bicêtre, Le Kremlin-Bicêtre
| | - I Baumgaertner
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Oncology, Hôpital Henri Mondor, Créteil
| | - R Coriat
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Cochin, Paris
| | - D Tougeron
- AGEO (Association des Gastroentérologues Oncologues), Paris; Depatment of Gastroenterology, Centre Hospitalo-Universitaire de Poitiers, Poitiers
| | - T Lecomte
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Centre Hospitalo-Universitaire de Tours, Tours
| | - F Mary
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Avicenne, Bobigny
| | - T Aparicio
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Saint-Louis, Paris; Department of Gastroenterology, Hôpital Avicenne, Bobigny
| | - L Marthey
- AGEO (Association des Gastroentérologues Oncologues), Paris; Depatment of Gastroenterology, Hôpital Antoine Béclère, Clamart
| | - V Taly
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris
| | - H Blons
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris; Department of Biochemistry, Hôpital Européen Georges Pompidou, Paris, France
| | - D Vernerey
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - P Laurent-Puig
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris.
| |
Collapse
|
|
9
|
Souto EB, Dias-Ferreira J, Craveiro SA, Severino P, Sanchez-Lopez E, Garcia ML, Silva AM, Souto SB, Mahant S. Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems. Pathogens 2019; 8:pathogens8030119. [PMID: 31374930 PMCID: PMC6789685 DOI: 10.3390/pathogens8030119] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2019] [Revised: 07/29/2019] [Accepted: 07/31/2019] [Indexed: 02/02/2023] Open
Abstract
The incidence of neglected diseases in tropical countries, such as Leishmaniasis and Chagas's disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health care systems. Both Leishmaniasis and Chagas's disease are caused by different protozoa and develop diverse symptoms, which depend on the specific species infecting man. Currently available drugs to treat these disorders have limited therapeutic outcomes, frequently due to microorganisms' drug resistance. In recent years, significant efforts have been made towards the development of innovative drug delivery systems aiming to improve bioavailability and pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of Leishmaniasis and Chagas's disease, the currently available pharmacological therapies and the new drug delivery systems for conventional drugs.
Collapse
Affiliation(s)
- Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
- CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| | - João Dias-Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - Sara A Craveiro
- Faculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 296, Paranhos, 4200-150 Porto, Portugal
| | - Patrícia Severino
- Laboratory of Nanotechnology and Nanomedicine (LNMED), Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49010-390, Brazil
- University of Tiradentes (UNIT), Industrial Biotechnology Program, Av. Murilo Dantas 300, Aracaju 49032-490, Brazil
| | - Elena Sanchez-Lopez
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain
| | - Maria L Garcia
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain
| | - Amélia M Silva
- Departamento de Biologia e Ambiente, Universidade de Trás-os-Montes e Alto Douro (UTAD), P.O. Box 1013; 5001-801 Vila Real, Portugal
- Centro de Investigação e de Tecnologias Agro-Ambientais e Biológicas (CITAB-UTAD), 5001-801 Vila Real, Portugal
| | - Selma B Souto
- Department of Endocrinology of Braga Hospital, Sete Fontes, 4710-243 São Victor, Braga, Portugal
| | - Sheefali Mahant
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana 124001, India
| |
Collapse
|
|
10
|
Fernandes AR, Santos AC, Sanchez-Lopez E, Kovačević AB, Espina M, Calpena AC, Veiga FJ, Garcia ML, Souto EB. Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers. Skin Pharmacol Physiol 2017; 31:59-73. [PMID: 29262420 DOI: 10.1159/000479529] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 07/13/2017] [Indexed: 12/30/2022]
Abstract
Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.
Collapse
Affiliation(s)
- Ana R Fernandes
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Coimbra, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|
|
11
|
Mohd Hanafiah K, Liu JJ, Lieschke K, Barnes NC, Garcia ML, Anderson DA. Serological biomarker screening and host factor analysis elucidating immune response heterogeneity in active pulmonary tuberculosis. Trop Biomed 2017; 34:556-569. [PMID: 33592924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
While mortality and morbidity from pulmonary tuberculosis (PTB) have improved, diagnosis of this infectious disease remains suboptimal without a point-of-care test. Antibody/ antigen-based serodiagnostics is the most amenable for point-of-care translation but hampered by a lack of validated biomarkers and a heterogeneous patient antibody response. Using a case-control design, we assessed serodiagnostic potential of immunoglobulins G, A, and dimeric IgA responses against 18 antigenic preparations, followed by antibody-subclass responses against antigen 60 (A60), and four markers of host innate immunity by enzymelinked immunoassay using sera samples (n=110) collected from April to October 2007 in VietNam from human immunodeficiency-negative patients with provisional diagnosis of PTB. We further analyzed host variables to investigate factors driving biomarker heterogeneity observed in patients. Among active pulmonary tuberculosis patients, low correlation was observed between anti-A60 antibody-classes, and between anti-A60 immunoglobulin G subclasses, but anti-A60 immunoglobulin A subclasses were significantly correlated. The best diagnostic combination of anti-A60 immunoglobulin G/A and a C-reactive protein "ruleout" remains insufficient at 82%/92% sensitivity/specificity (95%CI: 72-92%/82-98%). Heterogeneity of anti-A60 immunoglobulins G2, G3, M, as well as C-reactive protein and serum amyloid A levels observed in this study population appeared to be significantly associated with history of previous tuberculosis, hemoptysis, age, vaccination, night sweats, smoking, chest pain, fever, alcohol, and solid culture count. Further research on tuberculosis serological biomarkers may require consideration of host factors and new approaches using multiple biomarkers.
Collapse
Affiliation(s)
- K Mohd Hanafiah
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
- Universiti Sains Malaysia, School of Biological Sciences, 11600, Pulau Pinang, Malaysia
- Monash University, Faculty of Medicine, Nursing and Health Sciences, Department of Immunology, Clayton, Victoria, Australia 3800
| | - J J Liu
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
| | - K Lieschke
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
| | - N C Barnes
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
| | - M L Garcia
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
| | - D A Anderson
- Macfarlane Burnet Institute, Life Sciences, 85 Commercial Road, Melbourne, Victoria, Australia 3004
| |
Collapse
|
|
12
|
Toedebusch CM, Bachrach MD, Garcia VB, Johnson GC, Katz ML, Shaw G, Coates JR, Garcia ML. Cerebrospinal Fluid Levels of Phosphorylated Neurofilament Heavy as a Diagnostic Marker of Canine Degenerative Myelopathy. J Vet Intern Med 2017; 31:513-520. [PMID: 28186658 PMCID: PMC5354061 DOI: 10.1111/jvim.14659] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 12/05/2016] [Accepted: 12/22/2016] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND No definitive, antemortem diagnostic test for canine degenerative myelopathy (DM) is available. Phosphorylated neurofilament heavy (pNF-H) is a promising biomarker for nervous system diseases. HYPOTHESIS/OBJECTIVE Cerebrospinal fluid (CSF) and serum pNF-H is a detectable biological marker for diagnosis of canine DM. ANIMALS Fifty-three DM-affected, 27 neurologically normal, 7 asymptomatic at-risk, and 12 DM mimic dogs. METHODS Archived CSF and serum pNF-H concentrations were determined by a commercially available ELISA. A receiver-operating characteristic (ROC) curve was generated with CSF values. RESULTS Compared with old control dogs, median CSF pNF-H concentration was increased in all stages of DM; old dogs 5.1 ng/mL (interquartile range [IQR] 1.4-9.3) versus DM stage 1 23.9 ng/mL (IQR 20.8-29.6; P < .05) versus DM stage 2 36.8 ng/mL (IQR 22.9-51.2; P < .0001) versus DM stage 3 25.2 ng/mL (IQR 20.2-61.8; P < .001) versus DM stage 4 38.0 ng/mL (IQR 11.6-59.9; P < .01). Degenerative myelopathy stage 1 dogs had increased median CSF pNF-H concentrations compared with asymptomatic, at-risk dogs (3.4 ng/mL [IQR 1.5-10.9; P < .01]) and DM mimics (6.6 ng/mL [IQR 3.0-12.3; P < .01]). CSF pNF-H concentration >20.25 ng/mL was 80.4% sensitive (confidence interval [CI] 66.09-90.64%) and 93.6% specific (CI 78.58-99.21%) for DM. Area under the ROC curve was 0.9467 (CI 0.92-0.9974). No differences in serum pNF-H concentration were found between control and DM-affected dogs. CONCLUSIONS AND CLINICAL IMPORTANCE pNF-H concentration in CSF is a sensitive biomarker for diagnosis of DM. Although there was high specificity for DM in this cohort, further study should focus on a larger cohort of DM mimics, particularly other central and peripheral axonopathies.
Collapse
Affiliation(s)
- C M Toedebusch
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO
| | - M D Bachrach
- Division of Biological Sciences, Bond Life Sciences Center, University of Missouri-Columbia, Columbia, MO
| | - V B Garcia
- Division of Biological Sciences, Bond Life Sciences Center, University of Missouri-Columbia, Columbia, MO
| | - G C Johnson
- Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO
| | - M L Katz
- Mason Eye Institute, School of Medicine, University of Missouri-Columbia, Columbia, MO
| | - G Shaw
- EnCor Biotechnology Inc, Gainesville, FL
| | - J R Coates
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO
| | - M L Garcia
- Division of Biological Sciences, Bond Life Sciences Center, University of Missouri-Columbia, Columbia, MO
| |
Collapse
|
|
13
|
Villalón E, Jones MR, Sibigtroth C, Zino SJ, Dale JM, Landayan DS, Shen H, Cornelison DDW, Garcia ML. Muscle spindle alterations precede onset of sensorimotor deficits in Charcot-Marie-Tooth type 2E. Genes Brain Behav 2016; 16:260-270. [PMID: 27643807 DOI: 10.1111/gbb.12341] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 09/11/2016] [Accepted: 09/14/2016] [Indexed: 02/01/2023]
Abstract
Charcot-Marie-Tooth (CMT) is the most common inherited peripheral neuropathy, affecting approximately 2.8 million people. The CMT leads to distal neuropathy that is characterized by reduced motor nerve conduction velocity, ataxia, muscle atrophy and sensory loss. We generated a mouse model of CMT type 2E (CMT2E) expressing human neurofilament light E396K (hNF-LE396K ), which develops decreased motor nerve conduction velocity, ataxia and muscle atrophy by 4 months of age. Symptomatic hNF-LE396K mice developed phenotypes that were consistent with proprioceptive sensory defects as well as reduced sensitivity to mechanical stimulation, while thermal sensitivity and auditory brainstem responses were unaltered. Progression from presymptomatic to symptomatic included a 50% loss of large diameter sensory axons within the fifth lumbar dorsal root of hNF-LE396K mice. Owing to proprioceptive deficits and loss of large diameter sensory axons, we analyzed muscle spindle morphology in presymptomatic and symptomatic hNF-LE396K and hNF-L control mice. Muscle spindle cross-sectional area and volume were reduced in all hNF-LE396K mice analyzed, suggesting that alterations in muscle spindle morphology occurred prior to the onset of typical CMT pathology. These data suggested that CMT2E pathology initiated in the muscle spindles altering the proprioceptive sensory system. Early sensory pathology in CMT2E could provide a unifying hypothesis for the convergence of pathology observed in CMT.
Collapse
Affiliation(s)
- E Villalón
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| | - M R Jones
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| | - C Sibigtroth
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO, USA
| | - S J Zino
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| | - J M Dale
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| | - D S Landayan
- Quantitative and Systems Biology, University of California Merced, Merced, CA, USA
| | - H Shen
- Institute of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
| | - D D W Cornelison
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| | - M L Garcia
- Division of Biological Sciences, Columbia, MO, USA.,C. S. Bond Life Sciences Center, Columbia, MO, USA
| |
Collapse
|
|
14
|
Tang H, Zhu Y, Teumelsan N, Walsh SP, Shahripour A, Priest BT, Swensen AM, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Pai LY, Hampton C, Corona A, Hernandez M, Metzger J, Forrest M, Zhou X, Owens K, Tong V, Parmee E, Roy S, Kaczorowski GJ, Yang L, Alonso-Galicia M, Garcia ML, Pasternak A. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure. ACS Med Chem Lett 2016; 7:697-701. [PMID: 27437080 DOI: 10.1021/acsmedchemlett.6b00122] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Accepted: 05/12/2016] [Indexed: 12/25/2022] Open
Abstract
ROMK, the renal outer medullary potassium channel, is involved in potassium recycling at the thick ascending loop of Henle and potassium secretion at the cortical collecting duct in the kidney nephron. Because of this dual site of action, selective inhibitors of ROMK are expected to represent a new class of diuretics/natriuretics with superior efficacy and reduced urinary loss of potassium compared to standard-of-care loop and thiazide diuretics. Following our earlier work, this communication will detail subsequent medicinal chemistry endeavors to further improve lead selectivity against the hERG channel and preclinical pharmacokinetic properties. Pharmacological assessment of highlighted inhibitors will be described, including pharmacodynamic studies in both an acute rat diuresis/natriuresis model and a subchronic blood pressure model in spontaneous hypertensive rats. These proof-of-biology studies established for the first time that the human and rodent genetics accurately predict the in vivo pharmacology of ROMK inhibitors and supported identification of the first small molecule ROMK inhibitor clinical candidate, MK-7145.
Collapse
Affiliation(s)
- Haifeng Tang
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Yuping Zhu
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Nardos Teumelsan
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Shawn P. Walsh
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Aurash Shahripour
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Birgit T. Priest
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Andrew M. Swensen
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - John P. Felix
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Richard M. Brochu
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Timothy Bailey
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Brande Thomas-Fowlkes
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Lee-Yuh Pai
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Caryn Hampton
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Aaron Corona
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Melba Hernandez
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Joseph Metzger
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Michael Forrest
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Xiaoyan Zhou
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Karen Owens
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Vincent Tong
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Emma Parmee
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Sophie Roy
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Gregory J. Kaczorowski
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Lihu Yang
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Magdalena Alonso-Galicia
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Maria L. Garcia
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Alexander Pasternak
- Departments of Discovery Chemistry, ‡Ion Channels, §In Vivo Pharmacology, ∥Cardiorenal, and ⊥Pharmacokinetics,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
|
15
|
Rodriguez RP, Vich DV, Garcia ML, Varesche MBA, Zaiat M. Application of horizontal-flow anaerobic immobilized biomass reactor for bioremediation of acid mine drainage. J Water Health 2016; 14:399-410. [PMID: 27280606 DOI: 10.2166/wh.2015.241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The production of low-pH effluent with sulfate and metals is one of the biggest environmental concerns in the mining industry. The biological process for sulfate reduction has the potential to become a low-cost solution that enables the recovery of interesting compounds. The present study analyzed such a process in a horizontal-flow anaerobic immobilized biomass (HAIB) reactor, employing ethanol as the carbon and energy source. Results showed that a maximal efficiency in the removal of sulfate and ethanol could only be obtained by reducing the applied sulfate load (225.1 ± 38 g m(-3) d(-1)). This strategy led to over 75% of chemical oxygen demand (COD) and sulfate removal. Among the COD/SO4(2-) studied ratios, 0.67 showed the most promising performance. The effluent's pH has naturally remained between 6.8 and 7.0 and the complete oxidation of the organic matter has been observed. Corrections of the influent pH or effluent recirculation did not show any significant effect on the COD and sulfate removal efficiency. Species closely related to strains of Clostridium sp. and species of Acidaminobacter hydrogenomorfans and Fusibacter paucivorans that can be related to the process of sulfate reduction were found in the HAIB reactors when the initial pH was 5 and the COD/SO4(2-) ratio increased to 1.0.
Collapse
Affiliation(s)
- R P Rodriguez
- Universidade Federal de Alfenas (UNIFAL), Instituto de Ciência e Tecnologia (ICT), Campus Poços de Caldas, Rodovia José Aurélio Vilela, 11.999, CEP: 37715-400, Poços de Caldas, MG, Brazil E-mail:
| | - D V Vich
- Universidade de São Paulo (USP), Escola de Engenharia de São Carlos (EESC), Centro de Pesquisa, Desenvolvimento e Inovação em Engenharia Ambiental, Laboratório de Processos Biológicos, Av. João Dagnone, 1100, CEP: 13563-120, São Carlos, SP, Brazil
| | - M L Garcia
- Universidade Estadual Paulista (UNESP), Instituto de Geociências e Ciências Exatas, Departamento de Petrologia e Metalogenia, Av. 24A 1515, CEP: 13506-900, Rio Claro, SP, Brazil
| | - M B A Varesche
- Universidade de São Paulo (USP), Escola de Engenharia de São Carlos (EESC), Centro de Pesquisa, Desenvolvimento e Inovação em Engenharia Ambiental, Laboratório de Processos Biológicos, Av. João Dagnone, 1100, CEP: 13563-120, São Carlos, SP, Brazil
| | - M Zaiat
- Universidade de São Paulo (USP), Escola de Engenharia de São Carlos (EESC), Centro de Pesquisa, Desenvolvimento e Inovação em Engenharia Ambiental, Laboratório de Processos Biológicos, Av. João Dagnone, 1100, CEP: 13563-120, São Carlos, SP, Brazil
| |
Collapse
|
|
16
|
Walsh SP, Shahripour A, Tang H, de Jesus RK, Teumelsan N, Zhu Y, Frie J, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Ehrhart J, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorg Med Chem Lett 2016; 26:2339-43. [DOI: 10.1016/j.bmcl.2016.03.035] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 03/08/2016] [Accepted: 03/10/2016] [Indexed: 01/29/2023]
|
|
17
|
Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB. Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies. Int J Pharm 2016; 502:161-9. [PMID: 26921515 DOI: 10.1016/j.ijpharm.2016.02.039] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 02/21/2016] [Accepted: 02/22/2016] [Indexed: 01/08/2023]
Abstract
Cationic lipid nanoparticles (LNs) have been tested for sustained release and site-specific targeting of epigallocatechin gallate (EGCG), a potential polyphenol with improved pharmacological profile for the treatment of ocular pathologies, such as age-related macular edema, diabetic retinopathy, and inflammatory disorders. Cationic EGCG-LNs were produced by double-emulsion technique; the in vitro release study was performed in a dialysis bag, followed by the drug assay using a previously validated RP-HPLC method. In vitro HET-CAM study was carried out using chicken embryos to determine the potential risk of irritation of the developed formulations. Ex vivo permeation profile was assessed using rabbit cornea and sclera isolated and mounted in Franz diffusion cells. The results show that the use of cationic LNs provides a prolonged EGCG release, following a Boltzmann sigmoidal profile. In addition, EGCG was successfully quantified in both tested ocular tissues, demonstrating the ability of these formulations to reach both anterior and posterior segment of the eye. The pharmacokinetic study of the corneal permeation showed a first order kinetics for both cationic formulations, while EGCG-cetyltrimethylammonium bromide (CTAB) LNs followed a Boltzmann sigmoidal profile and EGCG-dimethyldioctadecylammonium bromide (DDAB) LNs a first order profile. Our studies also proved the safety and non-irritant nature of the developed LNs. Thus, loading EGCG in cationic LNs is recognised as a promising strategy for the treatment of ocular diseases related to anti-oxidant and anti-inflammatory pathways.
Collapse
Affiliation(s)
- Joana F Fangueiro
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB-UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal; Center for Neuroscience and Cell Biology (CNC), University of Coimbra (FFUC), Coimbra, Portugal
| | - Ana C Calpena
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Beatriz Clares
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Campus of Cartuja s/n, 18071 Granada, Spain
| | - Tatiana Andreani
- Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB-UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal; Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto (FCUP), Campo Alegre 4160-007 Porto, Portugal
| | - Maria A Egea
- Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Francisco J Veiga
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Center for Neuroscience and Cell Biology (CNC), University of Coimbra (FFUC), Coimbra, Portugal
| | - Maria L Garcia
- Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Amélia M Silva
- Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB-UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal; Department of Biology and Environment, University of Trás-os Montes e Alto Douro (UTAD), Quinta de Prados; 5001-801 Vila Real, Portugal
| | - Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Center for Neuroscience and Cell Biology (CNC), University of Coimbra (FFUC), Coimbra, Portugal.
| |
Collapse
|
|
18
|
Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, Swensen AM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Alonso-Galicia M, Zhou X, Pai LY, Corona A, Hampton C, Hernandez M, Bentley R, Chen J, Shah K, Metzger J, Forrest M, Owens K, Tong V, Ha S, Roy S, Kaczorowski GJ, Yang L, Parmee E, Garcia ML, Sullivan K, Pasternak A. Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation. ACS Med Chem Lett 2015; 6:747-52. [PMID: 26191360 DOI: 10.1021/ml500440u] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 05/07/2015] [Indexed: 12/12/2022] Open
Abstract
A new subseries of ROMK inhibitors exemplified by 28 has been developed from the initial screening hit 1. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of 28 as a new mechanism diuretic. Robust pharmacodynamic effects in both SD rats and dogs have been demonstrated.
Collapse
Affiliation(s)
- Shawn P. Walsh
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Aurash Shahripour
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Haifeng Tang
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Nardos Teumelsan
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Jessica Frie
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Yuping Zhu
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Lihu Yang
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Emma Parmee
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | | | | | - Alexander Pasternak
- Discovery Chemistry, ‡Department of Pharmacology, §Department of Cardiometabolic
Diseases, ∥Pharmacokinetic, Pharmacodynamics and Drug Metabolism, ⊥Department of Chemistry
Modeling and Informatics, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
|
19
|
Andreani T, Miziara L, Lorenzón EN, de Souza ALR, Kiill CP, Fangueiro JF, Garcia ML, Gremião PD, Silva AM, Souto EB. Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models. Eur J Pharm Biopharm 2015; 93:118-26. [PMID: 25843239 DOI: 10.1016/j.ejpb.2015.03.027] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Revised: 03/23/2015] [Accepted: 03/26/2015] [Indexed: 01/26/2023]
Abstract
The present paper focuses on the development and characterization of silica nanoparticles (SiNP) coated with hydrophilic polymers as mucoadhesive carriers for oral administration of insulin. SiNP were prepared by sol-gel technology under mild conditions and coated with different hydrophilic polymers, namely, chitosan, sodium alginate or poly(ethylene glycol) (PEG) with low and high molecular weight (PEG 6000 and PEG 20000) to increase the residence time at intestinal mucosa. The mean size and size distribution, association efficiency, insulin structure and insulin thermal denaturation have been determined. The mean nanoparticle diameter ranged from 289 nm to 625 nm with a PI between 0.251 and 0.580. The insulin association efficiency in SiNP was recorded above 70%. After coating, the association efficiency of insulin increased up to 90%, showing the high affinity of the protein to the hydrophilic polymer chains. Circular dichroism (CD) indicated that no conformation changes of insulin structure occurred after loading the peptide into SiNP. Nano-differential scanning calorimetry (nDSC) showed that SiNP shifted the insulin endothermic peak to higher temperatures. The influence of coating on the interaction of nanoparticles with dipalmitoylphosphatidylcholine (DPPC) biomembrane models was also evaluated by nDSC. The increase of ΔH values suggested a strong association of non-coated SiNP and those PEGylated nanoparticles coated with DPPC polar heads by forming hydrogen bonds and/or by electrostatic interaction. The mucoadhesive properties of nanoparticles were examined by studying the interaction with mucin in aqueous solution. SiNP coated with alginate or chitosan showed high contact with mucin. On the other hand, non-coated SiNP and PEGylated SiNP showed lower interaction with mucin, indicating that these nanoparticles can interdiffuse across mucus network. The results of the present work provide valuable data in assessing the in vitro performance of insulin-loaded SiNP coated with mucoadhesive polymers.
Collapse
Affiliation(s)
- Tatiana Andreani
- Department of Biology and Environment, University of Tras-os Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal
| | - Leonardo Miziara
- Department of Pharmaceutical Sciences, UNESP-Universidade Estadual Paulista, Rodovia Araraquara-Jau, Km. 01, Araraquara, São Paulo, Brazil
| | - Esteban N Lorenzón
- Department of Biochemistry and Chemical Technology, Institute of Chemistry, UNESP, Araraquara, São Paulo, Brazil
| | - Ana Luiza R de Souza
- Department of Pharmaceutical Sciences, UNESP-Universidade Estadual Paulista, Rodovia Araraquara-Jau, Km. 01, Araraquara, São Paulo, Brazil
| | - Charlene P Kiill
- Department of Pharmaceutical Sciences, UNESP-Universidade Estadual Paulista, Rodovia Araraquara-Jau, Km. 01, Araraquara, São Paulo, Brazil
| | - Joana F Fangueiro
- Research Centre for Biomedicine (CEBIMED), Fernando Pessoa University (UFP), Praça 9 de Abril, 349, P-4249-004 Porto, Portugal
| | - Maria L Garcia
- Department of Physical Chemistry, Faculty of Pharmacy, Barcelona University, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Palmira D Gremião
- Department of Pharmaceutical Sciences, UNESP-Universidade Estadual Paulista, Rodovia Araraquara-Jau, Km. 01, Araraquara, São Paulo, Brazil
| | - Amélia M Silva
- Department of Biology and Environment, University of Tras-os Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal
| | - Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Center for Neuroscience and Cell Biology & Institute for Biomedical Imaging and Life Sciences (CNC-IBILI), University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
| |
Collapse
|
|
20
|
Fangueiro JF, Parra A, Silva AM, Egea MA, Souto EB, Garcia ML, Calpena AC. Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate. Int J Pharm 2014; 475:181-90. [DOI: 10.1016/j.ijpharm.2014.08.053] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2014] [Revised: 08/23/2014] [Accepted: 08/27/2014] [Indexed: 11/16/2022]
|
|
21
|
Abrego G, Alvarado HL, Egea MA, Gonzalez-Mira E, Calpena AC, Garcia ML. Design of Nanosuspensions and Freeze-Dried PLGA Nanoparticles as a Novel Approach for Ophthalmic Delivery of Pranoprofen. J Pharm Sci 2014; 103:3153-64. [DOI: 10.1002/jps.24101] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 06/23/2014] [Accepted: 07/03/2014] [Indexed: 11/10/2022]
|
|
22
|
Andreani T, Souza ALRD, Kiill CP, Lorenzón EN, Fangueiro JF, Calpena AC, Chaud MV, Garcia ML, Gremião MPD, Silva AM, Souto EB. Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int J Pharm 2014; 473:627-35. [DOI: 10.1016/j.ijpharm.2014.07.049] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Revised: 07/25/2014] [Accepted: 07/26/2014] [Indexed: 02/01/2023]
|
|
23
|
Fangueiro JF, Andreani T, Fernandes L, Garcia ML, Egea MA, Silva AM, Souto EB. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B Biointerfaces 2014; 123:452-60. [PMID: 25303852 DOI: 10.1016/j.colsurfb.2014.09.042] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 08/04/2014] [Accepted: 09/19/2014] [Indexed: 11/15/2022]
Abstract
The encapsulation of epigallocatechin gallate (EGCG) in lipid nanoparticles (LNs) could be a suitable approach to avoid drug oxidation and epimerization, which are common processes that lead to low bioavailability of the drug limiting its therapeutic efficacy. The human health benefits of EGCG gained much interest in the pharmaceutical field, and so far there are no studies reporting its encapsulation in LNs. The purpose of this study has been the development of an innovative system for the ocular delivery of EGCG using LNs as carrier for the future treatment of several diseases, such as dry eye, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and macular oedema. LNs dispersions have been produced by multiple emulsion technique and previously optimized by a factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, two distinct cationic lipids were used, namely, cetyltrimethylammonium bromide (CTAB) and dimethyldioctadecylammonium bromide (DDAB). EGCG has been successfully loaded in the LNs dispersions and the nanoparticles analysis over 30 days of storage time predicted a good physicochemical stability. The particles were found to be in the nanometer range (<300 nm) and all the evaluated parameters, namely pH, osmolarity and viscosity, were compatible to the ocular administration. The evaluation of the cationic lipid used was compared regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. The results show that different lipids lead to different characteristics mainly associated with the acyl chain composition, i.e. double lipid shows to have influence in the crystallization and stability. Despite the recorded differences between DTAB and DDAB, both cationic LNs seem to fit the parameters for ocular drug delivery.
Collapse
Affiliation(s)
- Joana F Fangueiro
- CEBIMED, Research Centre for Biomedicine, Fernando Pessoa University, UFP-FCS, Praça 9 de Abril, 349, P-4249-004 Porto, Portugal; Faculty of Health Sciences, Fernando Pessoa University, UFP-FCS, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal
| | - Tatiana Andreani
- Faculty of Health Sciences, Fernando Pessoa University, UFP-FCS, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal; Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal
| | - Lisete Fernandes
- Electron Microscopy Unit, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal
| | - Maria L Garcia
- Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Maria A Egea
- Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | - Amélia M Silva
- Centre for Research and Technology of Agro-Environmental and Biological Sciences, CITAB, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal; Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal
| | - Eliana B Souto
- CEBIMED, Research Centre for Biomedicine, Fernando Pessoa University, UFP-FCS, Praça 9 de Abril, 349, P-4249-004 Porto, Portugal; Faculty of Pharmacy of University of Coimbra (FFUC), Polo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
| |
Collapse
|
|
24
|
Liu H, Zhou D, Garcia ML, Kohler MG, Shen X, Williams DS, Klimas MT, Hargreaves RJ, Kaczorowski GJ. Characteristic time courses of cortical and medullary sodium signals measured by noninvasive23Na-MRI in rat kidney induced by furosemide. J Magn Reson Imaging 2014; 41:1622-8. [PMID: 25168165 DOI: 10.1002/jmri.24732] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Accepted: 08/04/2014] [Indexed: 11/05/2022] Open
Affiliation(s)
- Haiying Liu
- Imaging; Merck Research Labs; Kenilworth New Jersey USA
| | - Dan Zhou
- In vivo Pharmacology; Merck Research Labs; Kenilworth New Jersey USA
| | - Maria L. Garcia
- Ion Channel Department; Merck Research Labs; Kenilworth New Jersey USA
| | - Martin G. Kohler
- Ion Channel Department; Merck Research Labs; Kenilworth New Jersey USA
| | - Xiaolan Shen
- Lab Animal Resources; Merck Research Labs; Kenilworth New Jersey USA
| | | | | | | | | |
Collapse
|
|
25
|
Garcia VB, Garcia ML, Schulz DJ. Quantitative expression profiling in mouse spinal cord reveals changing relationships among channel and receptor mRNA levels across postnatal maturation. Neuroscience 2014; 277:321-33. [PMID: 25043326 DOI: 10.1016/j.neuroscience.2014.07.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Revised: 07/02/2014] [Accepted: 07/09/2014] [Indexed: 11/28/2022]
Abstract
Neural networks ultimately arrive at functional output via interaction of the excitability of individual neurons and their synaptic interactions. We investigated the relationships between voltage-gated ion channel and neurotransmitter receptor mRNA levels in mouse spinal cord at four different postnatal time points (P5, P11, P17, and adult) and three different adult cord levels (cervical, thoracic, and lumbosacral) using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Our analysis and data visualization are novel in that we chose a focal group of voltage-gated channel subunits and transmitter receptor subunits, performed absolute quantitation of mRNA copy number for each gene from a sample, and used multiple correlation analyses and correlation matrices to detect patterns in correlated mRNA levels across all genes of interest. These correlation profiles suggest that postnatal maturation of the spinal cord includes changes among channel and receptor subunits that proceed from widespread co-regulation to more refined and distinct functional relationships.
Collapse
Affiliation(s)
- V B Garcia
- Division of Biological Sciences, University of Missouri, Columbia, MO 65211, USA
| | - M L Garcia
- Division of Biological Sciences, University of Missouri, Columbia, MO 65211, USA; C.S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA
| | - D J Schulz
- Division of Biological Sciences, University of Missouri, Columbia, MO 65211, USA.
| |
Collapse
|
|
26
|
Garcia ML, Kaczorowski GJ. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease. Curr Opin Pharmacol 2014; 15:1-6. [DOI: 10.1016/j.coph.2013.11.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 11/07/2013] [Accepted: 11/07/2013] [Indexed: 12/11/2022]
|
|
27
|
Monserrat JM, Garcia ML, Ventura-Lima J, González M, Ballesteros ML, Miglioranza KSB, Amé MV, Wunderlin DA. Antioxidant, phase II and III responses induced by lipoic acid in the fish Jenynsia multidentata (Anablapidae) and its influence on endolsulfan accumulation and toxicity. Pestic Biochem Physiol 2014; 108:8-15. [PMID: 24485309 DOI: 10.1016/j.pestbp.2013.10.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Revised: 10/21/2013] [Accepted: 10/22/2013] [Indexed: 06/03/2023]
Abstract
Antioxidants like lipoic acid (LA) are known to trigger augmented antioxidant and phase II and III responses. This study aimed to evaluate the effect of LA in P-glycoprotein (Pgp) expression, glutathione-S-transferase (GST) activity, total antioxidant competence, levels of lipid peroxides (TBARS) and accumulation of the organochlorine insecticide endosulfan (Endo: α-, β-isomers and sulfate metabolite) in different organs of the fish Jenynsia multidentata. One hundred and twenty females (1.55±0.07 g) were fed during 8 days with (n=60) or without (n=60) a LA enriched ration (6000 mg/kg). Four experimental groups were defined: -LA/-Endo; +LA/-Endo; -LA/+Endo; and +LA/+Endo. Endo groups were exposed during 24 h to 1.4 μg of insecticide/L. Results showed that only LA induced a significant increment in liver Pgp expression. GST activity was augmented in liver after exposure to LA or Endo. TBARS levels were lowered in liver and gills after LA pre-treatment. Total antioxidant capacity was lowered in liver of Endo exposed fish, a result that was reversed by LA pre-treatment. It is concluded that LA induced the expected effects in terms of Pgp expression, GST activity and reduced TBARS levels although favored α-Endo accumulation in brain. However, the Endo metabolism to the more persistent endosulfan sulfate was not facilitated by LA pre-treatment.
Collapse
Affiliation(s)
- J M Monserrat
- Curso de Pós-graduação em Ciências Fisiológicas - Fisiologia Animal Comparada, Universidade Federal do Rio Grande - FURG, Cx. P. 474, CEP 96.201-900, Rio Grande, RS, Brazil; Instituto de Ciências Biológicas (ICB), FURG, Brazil.
| | - M L Garcia
- Curso de Pós-graduação em Ciências Fisiológicas - Fisiologia Animal Comparada, Universidade Federal do Rio Grande - FURG, Cx. P. 474, CEP 96.201-900, Rio Grande, RS, Brazil; Instituto de Ciências Biológicas (ICB), FURG, Brazil
| | - J Ventura-Lima
- Curso de Pós-graduação em Ciências Fisiológicas - Fisiologia Animal Comparada, Universidade Federal do Rio Grande - FURG, Cx. P. 474, CEP 96.201-900, Rio Grande, RS, Brazil; Instituto de Ciências Biológicas (ICB), FURG, Brazil
| | - M González
- Laboratório de Ecotoxicología, Universidad Nacional de Mar del Plata, Instituto de Investigaciones Marinas y Costeras (IIMyC)-CONICET, Buenos Aires, Argentina
| | - M L Ballesteros
- Laboratório de Ecotoxicología, Universidad Nacional de Mar del Plata, Instituto de Investigaciones Marinas y Costeras (IIMyC)-CONICET, Buenos Aires, Argentina
| | - K S B Miglioranza
- Laboratório de Ecotoxicología, Universidad Nacional de Mar del Plata, Instituto de Investigaciones Marinas y Costeras (IIMyC)-CONICET, Buenos Aires, Argentina
| | - M V Amé
- Universidad Nacional de Córdoba - CONICET, Facultad Ciencias Químicas, Córdoba, Argentina
| | - D A Wunderlin
- Universidad Nacional de Córdoba - CONICET, Facultad Ciencias Químicas, Córdoba, Argentina
| |
Collapse
|
|
28
|
Shao PP, Ye F, Chakravarty PK, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL. Improved Cav2.2 Channel Inhibitors through a gem-Dimethylsulfone Bioisostere Replacement of a Labile Sulfonamide. ACS Med Chem Lett 2013; 4:1064-8. [PMID: 24900606 DOI: 10.1021/ml4002612] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Accepted: 09/08/2013] [Indexed: 12/22/2022] Open
Abstract
We report the investigation of sulfonamide-derived Cav2.2 inhibitors to address drug-metabolism liabilities with this lead class of analgesics. Modification of the benzamide substituent provided improvements in both potency and selectivity. However, we discovered that formation of the persistent 3-(trifluoromethyl)benzenesulfonamide metabolite was an endemic problem in the sulfonamide series and that the replacement of the center aminopiperidine scaffold failed to prevent this metabolic pathway. This issue was eventually addressed by application of a bioisostere strategy. The new gem-dimethyl sulfone series retained Cav2.2 potency without the liability of the circulating sulfonamide metabolite.
Collapse
Affiliation(s)
- Pengcheng P. Shao
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Feng Ye
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Prasun K. Chakravarty
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - James B. Herrington
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ge Dai
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Randal M. Bugianesi
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Rodolfo J. Haedo
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Andrew M. Swensen
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Vivien A. Warren
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - McHardy M. Smith
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Maria L. Garcia
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Owen B. McManus
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Kathryn A. Lyons
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Xiaohua Li
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Mitchell Green
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Nina Jochnowitz
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Erin McGowan
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Shruti Mistry
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Shu-Yu Sun
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Catherine Abbadie
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gregory J. Kaczorowski
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Joseph L. Duffy
- Departments of Medicinal Chemistry, ‡Ion Channels, §Drug Metabolism and
Pharmacokinetics, and ∥Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| |
Collapse
|
|
29
|
Garcia ML, Priest BT, Alonso-Galicia M, Zhou X, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Liu J, Swensen A, Pai LY, Xiao J, Hernandez M, Hoagland K, Owens K, Tang H, de Jesus RK, Roy S, Kaczorowski GJ, Pasternak A. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. J Pharmacol Exp Ther 2013; 348:153-64. [PMID: 24142912 DOI: 10.1124/jpet.113.208603] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The renal outer medullary potassium (ROMK) channel, which is located at the apical membrane of epithelial cells lining the thick ascending loop of Henle and cortical collecting duct, plays an important role in kidney physiology by regulating salt reabsorption. Loss-of-function mutations in the human ROMK channel are associated with antenatal type II Bartter's syndrome, an autosomal recessive life-threatening salt-wasting disorder with mild hypokalemia. Similar observations have been reported from studies with ROMK knockout mice and rats. It is noteworthy that heterozygous carriers of Kir1.1 mutations associated with antenatal Bartter's syndrome have reduced blood pressure and a decreased risk of developing hypertension by age 60. Although selective ROMK inhibitors would be expected to represent a new class of diuretics, this hypothesis has not been pharmacologically tested. Compound A [5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one)], a potent ROMK inhibitor with appropriate selectivity and characteristics for in vivo testing, has been identified. Compound A accesses the channel through the cytoplasmic side and binds to residues lining the pore within the transmembrane region below the selectivity filter. In normotensive rats and dogs, short-term oral administration of compound A caused concentration-dependent diuresis and natriuresis that were comparable to hydrochlorothiazide. Unlike hydrochlorothiazide, however, compound A did not cause any significant urinary potassium losses or changes in plasma electrolyte levels. These data indicate that pharmacologic inhibition of ROMK has the potential for affording diuretic/natriuretic efficacy similar to that of clinically used diuretics but without the dose-limiting hypokalemia associated with the use of loop and thiazide-like diuretics.
Collapse
Affiliation(s)
- Maria L Garcia
- Departments of Ion Channels (M.L.G., B.T.P., J.P.F., R.M.B., T.B., B.T.-F., J.L., A.S., G.J.K.), Hypertension (M.A.-G., X.Z., L.-Y.P., J.X., M.H., S.R.), Drug Metabolism (K.O.), and Medicinal Chemistry (H.T., R. K.J., A.P.), Merck Research Laboratories, Rahway, New Jersey; and Safety and Exploratory Pharmacology, Merck Research Laboratories, West Point, Pennsylvania (K.H.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
30
|
Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one. Bioorg Med Chem Lett 2013; 23:5829-32. [PMID: 24075732 DOI: 10.1016/j.bmcl.2013.08.104] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Revised: 08/23/2013] [Accepted: 08/27/2013] [Indexed: 10/26/2022]
Abstract
A sub-class of distinct small molecule ROMK inhibitors were developed from the original lead 1. Medicinal chemistry endeavors led to novel ROMK inhibitors with good ROMK functional potency and improved hERG selectivity. Two of the described ROMK inhibitors were characterized for the first in vivo proof-of-concept biology studies, and results from an acute rat diuresis model confirmed the hypothesis that ROMK inhibitors represent new mechanism diuretic and natriuretic agents.
Collapse
Affiliation(s)
- Haifeng Tang
- Department of Medicinal Chemistry, Rahway, NJ 07065, United States; Department of Ions Channels, Cardiovascular Disease, Rahway, NJ 07065, United States; Department of Drug Metabolism and Pharmacology, Rahway, NJ 07065, United States; Department of Merck Research Laboratories, Rahway, NJ 07065, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
31
|
Li XN, Herrington J, Petrov A, Ge L, Eiermann G, Xiong Y, Jensen MV, Hohmeier HE, Newgard CB, Garcia ML, Wagner M, Zhang BB, Thornberry NA, Howard AD, Kaczorowski GJ, Zhou YP. The role of voltage-gated potassium channels Kv2.1 and Kv2.2 in the regulation of insulin and somatostatin release from pancreatic islets. J Pharmacol Exp Ther 2012; 344:407-16. [PMID: 23161216 DOI: 10.1124/jpet.112.199083] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
The voltage-gated potassium channels Kv2.1 and Kv2.2 are highly expressed in pancreatic islets, yet their contribution to islet hormone secretion is not fully understood. Here we investigate the role of Kv2 channels in pancreatic islets using a combination of genetic and pharmacologic approaches. Pancreatic β-cells from Kv2.1(-/-) mice possess reduced Kv current and display greater glucose-stimulated insulin secretion (GSIS) relative to WT β-cells. Inhibition of Kv2.x channels with selective peptidyl [guangxitoxin-1E (GxTX-1E)] or small molecule (RY796) inhibitors enhances GSIS in isolated wild-type (WT) mouse and human islets, but not in islets from Kv2.1(-/-) mice. However, in WT mice neither inhibitor improved glucose tolerance in vivo. GxTX-1E and RY796 enhanced somatostatin release in isolated human and mouse islets and in situ perfused pancreata from WT and Kv2.1(-/-) mice. Kv2.2 silencing in mouse islets by adenovirus-small hairpin RNA (shRNA) specifically enhanced islet somatostatin, but not insulin, secretion. In mice lacking somatostatin receptor 5, GxTX-1E stimulated insulin secretion and improved glucose tolerance. Collectively, these data show that Kv2.1 regulates insulin secretion in β-cells and Kv2.2 modulates somatostatin release in δ-cells. Development of selective Kv2.1 inhibitors without cross inhibition of Kv2.2 may provide new avenues to promote GSIS for the treatment of type 2 diabetes.
Collapse
Affiliation(s)
- Xiaoyan Nina Li
- Department of Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
32
|
Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL. Aminopiperidine Sulfonamide Cav2.2 Channel Inhibitors for the Treatment of Chronic Pain. J Med Chem 2012; 55:9847-55. [DOI: 10.1021/jm301056k] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pengcheng P. Shao
- Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Feng Ye
- Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Prasun K. Chakravarty
- Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Deepu J. Varughese
- Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - James B. Herrington
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Ge Dai
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Randal M. Bugianesi
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Rodolfo J. Haedo
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Andrew M. Swensen
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Vivien A. Warren
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - McHardy M. Smith
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Maria L. Garcia
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Owen B. McManus
- Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Kathryn A. Lyons
- Drug Metabolism and
Pharmacokinetics, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Xiaohua Li
- Drug Metabolism and
Pharmacokinetics, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Mitchell Green
- Drug Metabolism and
Pharmacokinetics, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| | - Nina Jochnowitz
- Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Erin McGowan
- Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Shruti Mistry
- Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Shu-Yu Sun
- Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | - Catherine Abbadie
- Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United
States
| | | | - Joseph L. Duffy
- Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065,
United States
| |
Collapse
|
|
33
|
Felix JP, Priest BT, Solly K, Bailey T, Brochu RM, Liu CJ, Kohler MG, Kiss L, Alonso-Galicia M, Tang H, Pasternak A, Kaczorowski GJ, Garcia ML. The Inwardly Rectifying Potassium Channel Kir1.1: Development of Functional Assays to Identify and Characterize Channel Inhibitors. Assay Drug Dev Technol 2012; 10:417-31. [DOI: 10.1089/adt.2012.462] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- John P. Felix
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Birgit T. Priest
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Kelli Solly
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, Pennsylvania
| | - Timothy Bailey
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Richard M. Brochu
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Chou J. Liu
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Martin G. Kohler
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| | - Laszlo Kiss
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, Pennsylvania
| | | | - Haifeng Tang
- Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey
| | - Alexander Pasternak
- Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey
| | | | - Maria L. Garcia
- Department of Ion Channels, Merck Research Laboratories, North Wales, Pennsylvania
| |
Collapse
|
|
34
|
Araújo J, Garcia ML, Mallandrich M, Souto EB, Calpena AC. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine: Nanotechnology, Biology and Medicine 2012; 8:1034-41. [DOI: 10.1016/j.nano.2011.10.015] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Accepted: 10/25/2011] [Indexed: 11/25/2022]
|
|
35
|
Tang H, Walsh SP, Yan Y, de Jesus RK, Shahripour A, Teumelsan N, Zhu Y, Ha S, Owens KA, Thomas-Fowlkes BS, Felix JP, Liu J, Kohler M, Priest BT, Bailey T, Brochu R, Alonso-Galicia M, Kaczorowski GJ, Roy S, Yang L, Mills SG, Garcia ML, Pasternak A. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics. ACS Med Chem Lett 2012; 3:367-72. [PMID: 24900480 DOI: 10.1021/ml3000066] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2012] [Accepted: 03/28/2012] [Indexed: 11/28/2022] Open
Abstract
The renal outer medullary potassium channel (ROMK or Kir1.1) is a putative drug target for a novel class of diuretics that could be used for the treatment of hypertension and edematous states such as heart failure. An internal high-throughput screening campaign identified 1,4-bis(4-nitrophenethyl)piperazine (5) as a potent ROMK inhibitor. It is worth noting that this compound was identified as a minor impurity in a screening hit that was responsible for all of the initially observed ROMK activity. Structure-activity studies resulted in analogues with improved rat pharmacokinetic properties and selectivity over the hERG channel, providing tool compounds that can be used for in vivo pharmacological assessment. The featured ROMK inhibitors were also selective against other members of the inward rectifier family of potassium channels.
Collapse
Affiliation(s)
- Haifeng Tang
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Shawn P. Walsh
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Yan Yan
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Reynalda K. de Jesus
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Aurash Shahripour
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Nardos Teumelsan
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Yuping Zhu
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Sookhee Ha
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Karen A. Owens
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Brande S. Thomas-Fowlkes
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - John P. Felix
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Jessica Liu
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Martin Kohler
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Birgit T. Priest
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Timothy Bailey
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Richard Brochu
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Magdalena Alonso-Galicia
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Gregory J. Kaczorowski
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Sophie Roy
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Lihu Yang
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Sander G. Mills
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Maria L. Garcia
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| | - Alexander Pasternak
- Departments of †Medicinal Chemistry, ‡Hypertension, §Ion Channels, ⊥Preclinical DMPK, and ¶Chemistry Modeling, Merck Research Laboratories, Rahway
New Jersey 07065,
United States
| |
Collapse
|
|
36
|
Dale JM, Villalon E, Shannon SG, Barry DM, Markey RM, Garcia VB, Garcia ML. Expressing hNF-LE397K results in abnormal gaiting in a transgenic model of CMT2E. Genes Brain Behav 2012; 11:360-5. [PMID: 22288874 DOI: 10.1111/j.1601-183x.2012.00771.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Charcot-Marie-Tooth disease (CMT) is the most commonly inherited peripheral neuropathy. CMT disease signs include distal limb neuropathy, abnormal gaiting, exacerbation of neuropathy, sensory defects and deafness. We generated a novel line of CMT2E mice expressing an hNF-L(E397K) transgene, which displayed muscle atrophy of the lower limbs without denervation, proximal reduction in large caliber axons and decreased nerve conduction velocity. In this study, we showed that hNF-L(E397K) mice developed abnormal gait of the hind limbs. The identification of severe gaiting defects in combination with previously observed muscle atrophy, reduced axon caliber and decreased nerve conduction velocity suggests that hNF-L(E397K) mice recapitulate many of clinical signs associated with CMT2E. Therefore, hNF-L(E397K) mice provide a context for potential therapeutic intervention.
Collapse
Affiliation(s)
- J M Dale
- Division of Biological Sciences, University of Missouri-Columbia, Columbia, MO 65211, USA
| | | | | | | | | | | | | |
Collapse
|
|
37
|
Ponte CG, McManus OB, Schmalhofer WA, Shen DM, Dai G, Stevenson A, Sur S, Shah T, Kiss L, Shu M, Doherty JB, Nargund R, Kaczorowski GJ, Suarez-Kurtz G, Garcia ML. Selective, direct activation of high-conductance, calcium-activated potassium channels causes smooth muscle relaxation. Mol Pharmacol 2012; 81:567-77. [PMID: 22241372 DOI: 10.1124/mol.111.075853] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
High-conductance calcium-activated potassium (Maxi-K) channels are present in smooth muscle where they regulate tone. Activation of Maxi-K channels causes smooth muscle hyperpolarization and shortening of action-potential duration, which would limit calcium entry through voltage-dependent calcium channels leading to relaxation. Although Maxi-K channels appear to indirectly mediate the relaxant effects of a number of agents, activators that bind directly to the channel with appropriate potency and pharmacological properties useful for proof-of-concept studies are not available. Most agents identified to date display significant polypharmacy that severely compromises interpretation of experimental data. In the present study, a high-throughput, functional, cell-based assay for identifying Maxi-K channel agonists was established and used to screen a large sample collection (>1.6 million compounds). On the basis of potency and selectivity, a family of tetrahydroquinolines was further characterized. Medicinal chemistry efforts afforded identification of compound X, from which its two enantiomers, Y and Z, were resolved. In in vitro assays, Z is more potent than Y as a channel activator. The same profile is observed in tissues where the ability of either agent to relax precontracted smooth muscles, via a potassium channel-dependent mechanism, is demonstrated. These data, taken together, suggest that direct activation of Maxi-K channels represents a mechanism to be explored for the potential treatment of a number of diseases associated with smooth muscle hyperexcitability.
Collapse
Affiliation(s)
- Cristiano G Ponte
- Department of Biotechnology, Instituto Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
38
|
Kaczorowski GJ, Garcia ML, Bode J, Hess SD, Patel UA. The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling. Front Pharmacol 2011; 2:78. [PMID: 22171219 PMCID: PMC3236397 DOI: 10.3389/fphar.2011.00078] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 11/19/2011] [Indexed: 11/13/2022] Open
Abstract
Profiling of putative lead compounds against a representative panel of relevant enzymes, receptors, ion channels, and transporters is a pragmatic approach to establish a preliminary view of potential issues that might later hamper development. An early idea of which off-target activities must be minimized can save valuable time and money during the preclinical lead optimization phase if pivotal questions are asked beyond the usual profiling at hERG. The best data for critical evaluation of activity at ion channels is obtained using functional assays, since binding assays cannot detect all interactions and do not provide information on whether the interaction is that of an agonist, antagonist, or allosteric modulator. For ion channels present in human cardiac muscle, depending on the required throughput, manual-, or automated-patch-clamp methodologies can be easily used to evaluate compounds individually to accurately reveal any potential liabilities. The issue of expanding screening capacity against a cardiac panel has recently been addressed by developing a series of robust, high-throughput, cell-based counter-screening assays employing fluorescence-based readouts. Similar assay development approaches can be used to configure panels of efficacy assays that can be used to assess selectivity within a family of related ion channels, such as Nav1.X channels. This overview discusses the benefits of in vitro assays, specific decision points where profiling can be of immediate benefit, and highlights the development and validation of patch-clamp and fluorescence-based profiling assays for ion channels (for examples of fluorescence-based assays, see Bhave et al., 2010; and for high-throughput patch-clamp assays see Mathes, 2006; Schrøder et al., 2008).
Collapse
|
|
39
|
Herrington J, Solly K, Ratliff KS, Li N, Zhou YP, Howard A, Kiss L, Garcia ML, McManus OB, Deng Q, Desai R, Xiong Y, Kaczorowski GJ. Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol 2011; 80:959-64. [PMID: 21948463 DOI: 10.1124/mol.111.074831] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Identification of selective ion channel inhibitors represents a critical step for understanding the physiological role that these proteins play in native systems. In particular, voltage-gated potassium (K(V)2) channels are widely expressed in tissues such as central nervous system, pancreas, and smooth muscle, but their particular contributions to cell function are not well understood. Although potent and selective peptide inhibitors of K(V)2 channels have been characterized, selective small molecule K(V)2 inhibitors have not been reported. For this purpose, high-throughput automated electrophysiology (IonWorks Quattro; Molecular Devices, Sunnyvale, CA) was used to screen a 200,000-compound mixture (10 compounds per sample) library for inhibitors of K(V)2.1 channels. After deconvolution of 190 active samples, two compounds (A1 and B1) were identified that potently inhibit K(V)2.1 and the other member of the K(V)2 family, K(V)2.2 (IC(50), 0.1-0.2 μM), and that possess good selectivity over K(V)1.2 (IC(50) >10 μM). Modeling studies suggest that these compounds possess a similar three-dimensional conformation. Compounds A1 and B1 are >10-fold selective over Na(V) channels and other K(V) channels and display weak activity (5-9 μM) on Ca(V) channels. The biological activity of compound A1 on native K(V)2 channels was confirmed in electrophysiological recordings of rat insulinoma cells, which are known to express K(V)2 channels. Medicinal chemistry efforts revealed a defined structure-activity relationship and led to the identification of two compounds (RY785 and RY796) without significant Ca(V) channel activity. Taken together, these newly identified channel inhibitors represent important tools for the study of K(V)2 channels in biological systems.
Collapse
Affiliation(s)
- James Herrington
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey 07065, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
40
|
Abstract
Transporters represent attractive targets for drug discovery and are implicated in the pathophysiology of disorders across several therapeutic areas including asthma, cardiovascular disease, diabetes and neuroscience. However, the intrinsic mechanistic properties of transporters present significant challenges to the development of high-throughput screening methodologies. This review provides an update on potential transporter targets and evaluates the impact of available technologies to enable transporter screening, lead optimization and assessment of pharmacokinetics.
Collapse
Affiliation(s)
- Adam B Weinglass
- Merck Research Laboratories, Department of Ion Channels, Rahway, New Jersey 07065, USA.
| | | | | |
Collapse
|
|
41
|
Araújo J, Nikolic S, Egea MA, Souto EB, Garcia ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces 2011; 88:150-7. [PMID: 21764568 DOI: 10.1016/j.colsurfb.2011.06.025] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 06/19/2011] [Accepted: 06/20/2011] [Indexed: 01/31/2023]
Abstract
Triamcinolone acetonide (TA) is a corticosteroid drug currently administered by intravitreal injection for a broad spectrum of inflammatory, edematous and angiogenic ocular diseases. To increase the drug's bioavailability by ocular instillation, TA was encapsulated in nanostructured lipid carriers (NLC), previously optimized by our group using a factorial design approach. In the present paper, nanometric (∼200 nm), unimodal and negatively charged NLC loaded with the fluorescent lipid marker Nile red (NR-NLC) and drug (TA-NLC) were produced by high pressure homogenization. Based on the selected formulations, in vivo tests were carried out by eye-drop instillation of NR-NLC in mice, revealing the systems' ability of delivering lipophilic actives to the posterior segment of the eye via the corneal and non-corneal pathways. Short and long-term stability of TA-NLC was assessed by high performance stability analysis using the Turbiscan®. The results showed a backscattering of less than 1.5% and during a period of 6 months, anticipated the low tendency of these particles for aggregation during shelf life when stored at room temperature.
Collapse
Affiliation(s)
- Joana Araújo
- Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | | | | | | | | |
Collapse
|
|
42
|
Schmalhofer WA, Ratliff KS, Weinglass A, Kaczorowski GJ, Garcia ML, Herrington J. A KV2.1 gating modifier binding assay suitable for high throughput screening. Channels (Austin) 2011; 3:437-47. [PMID: 21150283 DOI: 10.4161/chan.3.6.10201] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Gating modifier peptides alter gating of voltage-gated potassium (KV) channels by binding to the voltage sensor paddle and changing the energetics of channel opening. Since the voltage sensor paddle is a modular motif with low sequence similarity across families, targeting of this region should yield highly specific channel modifiers. To test this idea, we developed a binding assay with the KV2.1 gating modifier, GxTX-1E. Monoiodotyrosine-GxTX-1E (125I-GxTX-1E) binds with high affinity (IC50 = 4 nM) to CHO cells stably expressing hKV2.1 channels, but not to CHO cells expressing Maxi-K channels. Binding of 125I-GxTX-1E to KV2.1 channels is inhibited by another KV2.1 gating modifier, stromatoxin (IC50 = 30 nM), but is not affected by iberiotoxin or charybdotoxin, pore blocking peptides of other types of potassium channels, or by ProTx-II, a selective gating modifier peptide of the voltage-gated sodium channel NaV1.7. Specific 125I-GxTX-1E binding is not detectable when CHO-KV2.1 cells are placed in high external potassium, suggesting that depolarization favors dissociation of the peptide. The binding assay was adapted to a 384-well format, allowing high throughput screening of large compound libraries. Interestingly, we discovered that compounds related to PAC, a di-substituted cyclohexyl KV channel blocker, displayed inhibitory binding activity. These data establish the feasibility of screening large libraries of compounds in an assay that monitors the displacement of a gating modifier from the channel's voltage sensor. Future screens using this approach will ultimately test whether the voltage sensor of KV channels can be selectively targeted by small molecules to modify channel function.
Collapse
|
|
43
|
Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML. A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-à-go-go Related Gene Potassium Channel. Assay Drug Dev Technol 2010; 8:714-26. [DOI: 10.1089/adt.2010.0351] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Andrew M. Swensen
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey
| | - Brande S. Thomas
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey
| | - John P. Felix
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey
| | - Rodolfo J. Haedo
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey
| | - Kelli Solly
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, Pennsylvania
| | - Laszlo Kiss
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, Pennsylvania
| | | | - Maria L. Garcia
- Department of Ion Channels, Merck Research Laboratories, Rahway, New Jersey
| |
Collapse
|
|
44
|
Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces 2010; 81:412-21. [PMID: 20719479 DOI: 10.1016/j.colsurfb.2010.07.029] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2010] [Revised: 06/29/2010] [Accepted: 07/12/2010] [Indexed: 10/19/2022]
Abstract
Packaging small drug molecules, such as non-steroidal anti-inflammatory drugs (NSAIDs) into nanoparticulate systems has been reported as a promising approach to improve the drug's bioavailability, biocompatibility and safety profiles. In the last 20 years, lipid nanoparticles (lipid dispersions) entered the nanoparticulate library as novel carrier systems due to their great potential as an alternative to other systems such as polymeric nanoparticles and liposomes for several administration routes. For ocular instillation nanoparticulate carriers are required to have a low mean particle size, with the lowest polydispersity as possible. The purpose of this work was to study the combined influence of 2-level, 4-factor variables on the formulation of flurbiprofen (FB), a lipophilic NSAID, in lipid carriers currently named as nanostructured lipid carriers (NLC). NLC were produced with stearic acid (SA) and castor oil (CO) stabilized by Tween® 80 (non-ionic surfactant) in aqueous dispersion. A 2(4) full factorial design based on 4 independent variables was used to plan the experiments, namely, the percentage of SA with regard to the total lipid, the FB concentration, the stabilizer concentration, and the storage conditions (i.e., storage temperature). The effects of these parameters on the mean particle size, polydispersity index (PI) and zeta potential (ZP) were investigated as dependent variables. The optimization process was achieved and the best formulation corresponded to the NLC formulation composed of 0.05 (wt%) FB, 1.6 (wt%) Tween® 80 and a 50:50 ratio of SA to CO, with an average diameter of 288 nm, PI 0.245 of and ZP of -29 mV. This factorial design study has proven to be a useful tool in optimizing FB-loaded NLC formulations. Stability of the optimized NLC was predicted using a TurbiScanLab® and the ocular tolerance was assessed in vitro and in vivo by the Eytex® and Draize test, respectively. The developed systems were shown physico-chemically stable with high tolerance for eye instillation.
Collapse
Affiliation(s)
- E Gonzalez-Mira
- Department of Physical Chemistry, Faculty of Pharmacy, Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
| | | | | | | |
Collapse
|
|
45
|
Shen H, Barry DM, Garcia ML. Distal to proximal development of peripheral nerves requires the expression of neurofilament heavy. Neuroscience 2010; 170:16-21. [PMID: 20633607 DOI: 10.1016/j.neuroscience.2010.07.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2010] [Revised: 07/02/2010] [Accepted: 07/07/2010] [Indexed: 01/15/2023]
Abstract
At the initiation of radial growth, neurofilaments are likely to consist primarily of neurofilament light and medium as neurofilament heavy expression is developmentally delayed. To better understand the role of neurofilament heavy in structuring axons, axonal diameter and neurofilament organization were measured in proximal and distal segments of the sciatic nerve and along the entire length of the phrenic nerve. Deletion of neurofilament heavy reduced axonal diameters and neurofilament number in proximal nerve segments. However, neurofilament spacing was greater in proximal versus distal phrenic nerve segments. Taken together, these results suggest that loss of neurofilament heavy reduces radial growth in proximal axonal segments by reducing the accumulation of neurofilaments. As neurofilament heavy expression is developmentally delayed, these results suggest that without neurofilament heavy, the neurofilament network is established in a distal to proximal gradient perhaps to allow distal axonal segments to develop prior to proximal segments.
Collapse
Affiliation(s)
- H Shen
- C.S. Bond Life Sciences Center, University of Missouri, 1201 Rollins Street, Columbia, MO 65211, USA
| | | | | |
Collapse
|
|
46
|
Barry DM, Carpenter C, Yager C, Golik B, Barry KJ, Shen H, Mikse O, Eggert LS, Schulz DJ, Garcia ML. Variation of the neurofilament medium KSP repeat sub-domain across mammalian species: implications for altering axonal structure. ACTA ACUST UNITED AC 2010; 213:128-36. [PMID: 20008369 DOI: 10.1242/jeb.033787] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The evolution of larger mammals resulted in a corresponding increase in peripheral nerve length. To ensure optimal nervous system functionality and survival, nerve conduction velocities were likely to have increased to maintain the rate of signal propagation. Increases of conduction velocities may have required alterations in one of the two predominant properties that affect the speed of neuronal transmission: myelination or axonal diameter. A plausible mechanism to explain faster conduction velocities was a concomitant increase in axonal diameter with evolving axonal length. The carboxy terminal tail domain of the neurofilament medium subunit is a determinant of axonal diameter in large caliber myelinated axons. Sequence analysis of mammalian orthologs indicates that the neurofilament medium carboxy terminal tail contains a variable lysine-serine-proline (KSP) repeat sub-domain flanked by two highly conserved sub-domains. The number of KSP repeats within this region of neurofilament medium varies among species. Interestingly, the number of repeats does not change within a species, suggesting that selective pressure conserved the number of repeats within a species. Mapping KSP repeat numbers onto consensus phylogenetic trees reveals independent KSP expansion events across several mammalian clades. Linear regression analyses identified three subsets of mammals, one of which shows a positive correlation in the number of repeats with head-body length. For this subset of mammals, we hypothesize that variations in the number of KSP repeats within neurofilament medium carboxy terminal tail may have contributed to an increase in axonal caliber, increasing nerve conduction velocity as larger mammals evolved.
Collapse
Affiliation(s)
- D M Barry
- Department of Biological Sciences, University of Missouri, Columbia, Columbia, MO 65211, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
|
47
|
Nardi A, Demnitz J, Garcia ML, Polosa R. Potassium channels as drug targets for therapeutic intervention in respiratory diseases. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543770802553798] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
|
48
|
Giangiacomo KM, Becker J, Garsky C, Schmalhofer W, Garcia ML, Mullmann TJ. Novel α-KTx Sites in the BK Channel and Comparative Sequence Analysis Reveal Distinguishing Features of the BK and KV Channel Outer Pore. Cell Biochem Biophys 2008; 52:47-58. [DOI: 10.1007/s12013-008-9026-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/28/2008] [Indexed: 01/30/2023]
|
|
49
|
Garcia ML, Lapa KR, Foresti E, Zaiat M. Effects of bed materials on the performance of an anaerobic sequencing batch biofilm reactor treating domestic sewage. J Environ Manage 2008; 88:1471-7. [PMID: 17765390 DOI: 10.1016/j.jenvman.2007.07.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2007] [Revised: 06/29/2007] [Accepted: 07/18/2007] [Indexed: 05/17/2023]
Abstract
The objective of this study was to determine the best performance of an anaerobic sequencing batch biofilm reactor (AnSBBR) based on the use of four different bed materials as support for biomass immobilization. The bed materials utilized were polyurethane foam (PU), vegetal carbon (VC), synthetic pumice (SP), and recycled low-density polyethylene (PE). The AnSBBR, with a total volume of 7.2L, was operated in 8-h batch cycles over 10 months, and fed with domestic sewage with an average influent chemical oxygen demand (COD) of 358+/-110 mg/L. The average effluent COD values were 121+/-31, 208+/-54, 233+/-52, and 227+/-51 mg/L, for PU, VC, SP, and PE, respectively. A modified first-order kinetic model was adjusted to temporal profiles of COD during a batch cycle, and the apparent kinetic constants were 0.52+/-0.05, 0.37+/-0.05, 0.80+/-0.04, and 0.30+/-0.02 h(-1) for PU, VC, SP, and PE, respectively. Specific substrate utilization rates of 1.08, 0.11, and 0.86 mg COD/mg VS day were obtained for PU, VC, and PE, respectively. Although SP yielded the highest kinetic coefficient, PU was considered the best support, since SP presented loss of chemical constituents during the reactor's operational phase. In addition, findings on the microbial community were associated with the reactor's performance data. Although PE did not show a satisfactory performance, an interesting microbial diversity was found on its surface. Based on the morphology and denaturing gradient gel electrophoresis (DGGE) results, PE showed the best capacity for promoting the attachment of methanogenic organisms, and is therefore a material that merits further analysis. PU was considered the most suitable material showing the best performance in terms of efficiency of solids and COD removal.
Collapse
Affiliation(s)
- M L Garcia
- Departamento de Hidráulica e Saneamento, Escola de Engenharia de São Carlos, Universidade de São Paulo, Av. Trabalhador São-Carlense, 400, CEP 13566 590 São Carlos-SP, Brazil
| | | | | | | |
Collapse
|
|
50
|
Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB, Kaczorowski GJ, Garcia ML, Koltzenburg M, Priest BT. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol 2008; 74:1476-84. [PMID: 18728100 DOI: 10.1124/mol.108.047670] [Citation(s) in RCA: 229] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Voltage-gated sodium (Na(V)1) channels play a critical role in modulating the excitability of sensory neurons, and human genetic evidence points to Na(V)1.7 as an essential contributor to pain signaling. Human loss-of-function mutations in SCN9A, the gene encoding Na(V)1.7, cause channelopathy-associated indifference to pain (CIP), whereas gain-of-function mutations are associated with two inherited painful neuropathies. Although the human genetic data make Na(V)1.7 an attractive target for the development of analgesics, pharmacological proof-of-concept in experimental pain models requires Na(V)1.7-selective channel blockers. Here, we show that the tarantula venom peptide ProTx-II selectively interacts with Na(V)1.7 channels, inhibiting Na(V)1.7 with an IC(50) value of 0.3 nM, compared with IC(50) values of 30 to 150 nM for other heterologously expressed Na(V)1 subtypes. This subtype selectivity was abolished by a point mutation in DIIS3. It is interesting that application of ProTx-II to desheathed cutaneous nerves completely blocked the C-fiber compound action potential at concentrations that had little effect on Abeta-fiber conduction. ProTx-II application had little effect on action potential propagation of the intact nerve, which may explain why ProTx-II was not efficacious in rodent models of acute and inflammatory pain. Mono-iodo-ProTx-II ((125)I-ProTx-II) binds with high affinity (K(d) = 0.3 nM) to recombinant hNa(V)1.7 channels. Binding of (125)I-ProTx-II is insensitive to the presence of other well characterized Na(V)1 channel modulators, suggesting that ProTx-II binds to a novel site, which may be more conducive to conferring subtype selectivity than the site occupied by traditional local anesthetics and anticonvulsants. Thus, the (125)I-ProTx-II binding assay, described here, offers a new tool in the search for novel Na(V)1.7-selective blockers.
Collapse
|